Gastrointestinal toxicities of novel agents in cancer therapy.
Asnacios
Amani
A
AP-HP, Hôpital Antoine Béclère, Service d'hépato-gastroentérologie, Clamart, F-92140, France.
Naveau
Sylvie
S
Perlemuter
Gabriel
G
D020533:Angiogenesis Inhibitors / Q000009:adverse effects; D000911:Antibodies, Monoclonal / Q000009:adverse effects; D000970:Antineoplastic Agents / Q000009:adverse effects*; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology; D003967:Diarrhea / Q000139:chemically induced; D004791:Enzyme Inhibitors / Q000009:adverse effects; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D005767:Gastrointestinal Diseases / Q000139:chemically induced*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D010770:Phosphotransferases / Q000037:antagonists & inhibitors; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*; D014945:Wound Healing / Q000187:drug effects
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D042461:Vascular Endothelial Growth Factor A; D010770:Phosphotransferases; D066246:ErbB Receptors